Abstract
Gemcitabine+cisplatin (GC) or carboplatin (GCa) are the global 1L standard of care (SOC) therapies for la/mUC; however, prognosis is poor and <50% of patients receive 1L chemotherapy. Several alternative 1L regimens are recognized by guidelines/used in practice, and new therapies are emerging. This SLR and NMA of randomized controlled trials (RCTs) compared outcomes of alternative 1L regimens with SOC to better understand the unmet need.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
